Clinical trials: Placebo Group
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Systemic Sclerosis
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites.
- Trial name
- focuSSced (NCT02453256)
- Testing
- Tocilizumab
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 212 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and of a late boost vaccination; and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine…
- Trial name
- IPCAVD-012 (NCT02935686)
- Testing
- Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant
- Where
- 13 sites in United States, Kenya and 1 more
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hypertension
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
- Trial name
- NCT00219024
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 2,775 people
- Sponsor
- Novartis
Impotence
Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED.
- Trial name
- NCT00301262
- Testing
- Viagra (Sildenafil citrate)
- Where
- 26 sites in Canada
- Volunteers
- 183 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Corticobasal Syndrome (CBS)
PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)
Corticobasal syndrome (CBS) is a rapidly progressive neurodegenerative disorder with an average survival time of about 6-8 years after the first clinical manifestation. No potent symptomatic treatment is currently available.
- Trial name
- PROFIL (NCT05983588)
- Testing
- RAVICTI 1.1 g/ml
- Where
- 2 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Technical University of Munich
Healthy
Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241
The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including the effect of food.
- Trial name
- NCT00914303
- Testing
- AZD3241
- Where
- Sweden
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Parkinson Disease
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
- Trial name
- NCT00321854
- Testing
- pramipexole
- Where
- 99 sites in United States, Austria and 8 more
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Migraine, Common Migraine
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of two doses of topiramate (100 and 200 mg daily) versus placebo and propranolol in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236561
- Testing
- topiramate, propranolol
- Volunteers
- 786 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Asthma
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
- Trial name
- NCT07098403
- Testing
- SHR-1905 Injection
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Type 2 Diabetes
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join.
- Trial name
- NCT07754461
- Testing
- Survodutide
- Where
- 101 sites in United States, Australia and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Colorectal Adenoma
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as…
- Trial name
- NCT00282386
- Testing
- MK0966; Rofecoxib / Duration of Treatment: 156 weeks
- Volunteers
- 2,586 people
- Sponsor
- Merck Sharp & Dohme LLC
Efficacy, Safety
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
This is a randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients with diabetes mellitus…
- Conditions
- Efficacy, Safety, Pharmacokinetics, Diabetes Mellitus, Type 2
- Trial name
- NCT05353686
- Testing
- XEN-D0501
- Where
- 10 sites in Lithuania
- Volunteers
- 54 people
- Sponsor
- Pila Pharma
Asthma
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects…
- Trial name
- NCT03535870
- Testing
- Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
- Where
- United States
- Volunteers
- 1,556 people
- Sponsor
- West-Ward Pharmaceutical
Primary Sjögren's Syndrome
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
- Trial name
- rho (NCT05817669)
- Testing
- Efgartigimod
- Where
- 17 sites in Belgium, Hungary and 2 more
- Volunteers
- 34 people
- Sponsor
- argenx
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Hypertension
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
- Trial name
- NCT01373086
- Testing
- LFF269, Eplerenone
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00239473
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 38 sites in Germany, Italy and 2 more
- Volunteers
- 429 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers.
- Trial name
- NCT01161069
- Testing
- PF-03049423
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections, Peripheral Neuropathy
Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy
Study to determine if pregabalin is more effective than placebo in treating subjects with nerve pain associated with HIV neuropathy.
- Trial name
- NCT00232141
- Testing
- pregabalin
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 302 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.